Spots Global Cancer Trial Database for Everolimus in Treating Patients With Recurrent Low-Grade Glioma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Everolimus in Treating Patients With Recurrent Low-Grade Glioma
Official Title: Phase II Trial of RAD001 in Patients With Recurrent Low Grade Glioma
Study ID: NCT00823459
Study Description
Brief Summary: This phase II trial studies how well everolimus works in treating patients with recurrent low-grade glioma. Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth or by blocking blood flow to the tumor.
Detailed Description: PRIMARY OBJECTIVES: 1. To determine progression-free survival at 6 months associated with use of RAD001 (everolimus) in patients initially diagnosed with low-grade glioma who undergo biopsy or subtotal resection at the time of recurrence with pathologic evidence of recurrent low-grade glioma (LGG). SECONDARY OBJECTIVES: 1. To further delineate the safety profile of RAD001 in patients with recurrent LGG. 2. To assess overall survival (OS) in patients treated with RAD001. 3. To assess the objective response rate (ORR) in patients treated with RAD001. 4. To assess the correlation of protein kinase B (PKB)/Akt and phosphatase and tensin homolog (PTEN) expression with response, progression status by 6 months, and OS in patients treated with RAD001.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
University of California, San Francisco, San Francisco, California, United States
Contact Details
Name: Susan Chang, MD
Affiliation: University of California, San Francisco
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
